Doxazosin an a1 Antagonist for Alcohol Dependence

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

November 1, 2011

Primary Completion Date

August 1, 2013

Study Completion Date

March 1, 2015

Conditions
Alcohol DependenceAnxiety
Interventions
DRUG

Doxazosin

Doxazosin were prepared as opaque capsules by a compounding pharmacy and inserted into blister packs. Consistent with the recommended titration, doxazosin was titrated up to 16 mg daily (or maximum tolerable dose) during the first 4 weeks. A 1-week downward titration for safety reasons was also planned. Study medication adherence was assessed by self-report and pill count. Additionally, capsules contained 25mg riboflavin as a marker of adherence through urine sample.

DRUG

Placebo

Matched placebo were prepared as opaque capsules by a compounding pharmacy and inserted into blister packs. Consistent with the recommended titration, doxazosin or matched placebo was titrated up to 16 mg daily (or maximum tolerable dose) during the first 4 weeks. A 1-week downward titration for safety reasons was also planned. Study medication adherence was assessed by self-report and pill count. Additionally, capsules contained 25mg riboflavin as a marker of adherence through urine sample.

Trial Locations (2)

02903

Brown University Center for Alcohol and Addiction Studies, Providence

02912

Brown University Center for Alcohol and Addiction Studies, Providence

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

National Institute on Alcohol Abuse and Alcoholism (NIAAA)

NIH

lead

Brown University

OTHER